이스라엘 - 영어 - Ministry of Health

neopharm (israel) 1996 ltd - meropenem as anhydrous - powder for solution for inj/inf - meropenem as anhydrous 500 mg/vial - meropenem - for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

as kalceks - meropenem trihydrate - powder for solution for injection/infusion - meropenem

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

steriscience b.v. - meropenem trihydrate - powder for solution for injection/infusion - meropenem

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

rowex ltd - meropenem trihydrate - powder for solution for injection/infusion - meropenem

이스라엘 - 영어 - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - meropenem as trihydrate - powder for solution for inj/inf - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis -septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency

이스라엘 - 영어 - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - meropenem as trihydrate - powder for solution for inj/inf - meropenem as trihydrate 500 mg/vial - meropenem - meropenem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis -septicemia. meropenem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency

뉴질랜드 - 영어 - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - meropenem trihydrate 1.14155 g equivalent to of meroopenem 1 g;   - powder for injection - 1 g - active: meropenem trihydrate 1.14155 g equivalent to of meroopenem 1 g   excipient: nitrogen sodium carbonate - indicated for treatment, in adults and children, of lower respiratory tract infections.

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - meropenem - powder for solution for injection/infusion - 0.5 gram(s) - carbapenems; meropenem

케냐 - 영어 - Pharmacy and Poisons Board

kopran limited c/o. surgilinks ltd kopran limited 1076,parijat house, dr. e.moses - meropenem for injection usp - powder for solution for injection/infusion - meropenem 500 mg (as meropenem trihydrate) - meropenem

아일랜드 - 영어 - HPRA (Health Products Regulatory Authority)

hospira uk limited - meropenem trihydrate - pdr for soln inj/inf - 500 milligram - meropenem